Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Sep 17, 2018 (8 years ago)

treatNOW ABILIFY

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

treatNOW ABILIFY (aripiprazole) / ABILIFY MAINTENA 400-mg (aripiprazole) for extended release injectable suspension. Kit contents 2 packs Abilify Tablets 10 mg (14 day supply) plus 1 Abilfy Maintena Vial Kit.Rx only. Distributed and Marketed by: Otsuka America Pharmaceutical, Inc. Rockville, MD 20850 USA Marketed by: Lundbleck, Deerfield, IL 60015 USA Bar Code VialKit-59148-10Tabs-02

Drug: Aripiprazole

Recalling firm
Otsuka Pharmaceutical Development & Commercialization, Inc.
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0018-2019 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Aripiprazole recalls

See all
Class II · Moderate risk

Aripiprazole Tablets USP

Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.

Ongoing Labeling / mix-up Ajanta Pharma USA Inc NDC 27241-056-03 D-0594-2026
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-011-13 D-0469-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-009-13 D-0468-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-008-13 D-0467-2024

Other recalls by Otsuka Pharmaceutical Development & Commercialization, Inc.

All 2018 recalls
Class III · Low risk

treatNOW ABILIFY

Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Terminated Labeling / mix-up Otsuka Pharmaceutical Development & Commercialization, Inc. D-0017-2019